ARS Pharma Files 8-K on Financials
Ticker: SPRY · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1671858
| Field | Detail |
|---|---|
| Company | Ars Pharmaceuticals, Inc. (SPRY) |
| Form Type | 8-K |
| Filed Date | Jan 13, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, operations, disclosure
TL;DR
ARS Pharma dropped an 8-K detailing its financial condition and operations.
AI Summary
ARS Pharmaceuticals, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing also included Regulation FD disclosures and financial statements. The company was formerly known as Silverback Therapeutics, Inc. and changed its name on April 12, 2016.
Why It Matters
This filing provides investors with an update on ARS Pharmaceuticals' financial performance and operational status. It is crucial for understanding the company's current health and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not appear to contain any new or significant negative information.
Key Players & Entities
- ARS Pharmaceuticals, Inc. (company) — Registrant
- Silverback Therapeutics, Inc. (company) — Former company name
- January 13, 2025 (date) — Date of report
- April 12, 2016 (date) — Date of name change
- Delaware (jurisdiction) — State of incorporation
- San Diego, California (location) — Principal executive offices
FAQ
What specific financial results are being reported in this 8-K?
The filing indicates it pertains to 'Results of Operations and Financial Condition' but does not detail specific figures within the provided text.
What is the primary purpose of this 8-K filing?
The primary purpose is to report on the company's results of operations and financial condition, along with Regulation FD disclosures and financial statements.
When was ARS Pharmaceuticals, Inc. formerly known as Silverback Therapeutics, Inc.?
The company changed its name from Silverback Therapeutics, Inc. on April 12, 2016.
Where are ARS Pharmaceuticals, Inc.'s principal executive offices located?
The principal executive offices are located at 11682 El Camino Real, Suite 120, San Diego, California.
What is the SEC file number for ARS Pharmaceuticals, Inc.?
The SEC file number for ARS Pharmaceuticals, Inc. is 001-39756.
Filing Stats: 657 words · 3 min read · ~2 pages · Grade level 10.5 · Accepted 2025-01-13 08:08:13
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share SPRY The Nasdaq
Filing Documents
- d910559d8k.htm (8-K) — 26KB
- d910559dex991.htm (EX-99.1) — 33KB
- d910559dex992.htm (EX-99.2) — 24KB
- g910559ex99_2s10g1.jpg (GRAPHIC) — 124KB
- g910559ex99_2s11g1.jpg (GRAPHIC) — 110KB
- g910559ex99_2s12g1.jpg (GRAPHIC) — 137KB
- g910559ex99_2s13g1.jpg (GRAPHIC) — 107KB
- g910559ex99_2s14g1.jpg (GRAPHIC) — 139KB
- g910559ex99_2s15g1.jpg (GRAPHIC) — 110KB
- g910559ex99_2s1g1.jpg (GRAPHIC) — 84KB
- g910559ex99_2s2g1.jpg (GRAPHIC) — 214KB
- g910559ex99_2s3g1.jpg (GRAPHIC) — 134KB
- g910559ex99_2s4g1.jpg (GRAPHIC) — 139KB
- g910559ex99_2s5g1.jpg (GRAPHIC) — 137KB
- g910559ex99_2s6g1.jpg (GRAPHIC) — 102KB
- g910559ex99_2s7g1.jpg (GRAPHIC) — 49KB
- g910559ex99_2s8g1.jpg (GRAPHIC) — 92KB
- g910559ex99_2s9g1.jpg (GRAPHIC) — 56KB
- g910559snap1.jpg (GRAPHIC) — 9KB
- 0001193125-25-005014.txt ( ) — 2627KB
- spry-20250113.xsd (EX-101.SCH) — 3KB
- spry-20250113_lab.xml (EX-101.LAB) — 18KB
- spry-20250113_pre.xml (EX-101.PRE) — 11KB
- d910559d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ARS PHARMACEUTICALS, INC. Date: January 13, 2025 By: /s/ Richard Lowenthal, M.S., MSEL Richard Lowenthal, M.S., MSEL President and Chief Executive Officer